Biomanufacturing

Gore PharmBIO Introduces 9.0 mL Protein Capture Device To Improve Throughput And Productivity In Bioprocessing Process Development

Retrieved on: 
Wednesday, May 13, 2020
Articles, Life sciences, Biology, Biotechnology, Biomanufacturing, Biopharmaceuticals, Food industry, Pharmaceutical industry, Chromatography, Protein A

This new 9.0 mL GORE Protein Capture Device will enable improved throughput and productivity in lead generation, optimization and early process development, with a demonstrated dynamic binding capacity of greater than 360 mg at 30 second residence time (18 mL/minute).

Key Points: 
  • This new 9.0 mL GORE Protein Capture Device will enable improved throughput and productivity in lead generation, optimization and early process development, with a demonstrated dynamic binding capacity of greater than 360 mg at 30 second residence time (18 mL/minute).
  • William Barrett, Ph.D., Product Specialist for Gore PharmBIO Products, noted some of the challenges in biomanufacturing that are driving Gore's chromatography product development roadmap.
  • "Protein A is often oversized or underutilized to gain flow and speed processing times to keep up pace with upstream productivity.
  • Recognizing that a new approach was needed, Gore launched the 1.0 mL and 3.5 mL GORE Protein Capture Devices with Protein A for drug discovery.

CEPI Announces COVID-19 Vaccine Development Partnership With Clover Biopharmaceuticals’ Australian Subsidiary

Retrieved on: 
Monday, April 27, 2020
Health, Infectious diseases, Research, Pharmaceutical, Science, Biotechnology, Articles, Life sciences, Biotechnology, Pharmaceutical industry, Biomanufacturing, Biopharmaceuticals, Food industry, Clover

CEPI will invest an initial US$3.5 million in a partnering agreement with Clover Biopharmaceuticals AUS Pty Ltd (Clover Australia) a wholly-owned subsidiary of Sichuan Clover Biopharmaceuticals, Inc (China) (Clover Biopharmaceuticals), bringing the organisations total investment in COVID-19 vaccine research & development to US$39.6m.

Key Points: 
  • CEPI will invest an initial US$3.5 million in a partnering agreement with Clover Biopharmaceuticals AUS Pty Ltd (Clover Australia) a wholly-owned subsidiary of Sichuan Clover Biopharmaceuticals, Inc (China) (Clover Biopharmaceuticals), bringing the organisations total investment in COVID-19 vaccine research & development to US$39.6m.
  • This innovative vaccine candidate is based on Clover Biopharmaceuticals proprietary Trimer-Tag vaccine technology platform, which is a novel way to produce the spike proteins of the COVID-19 virus in a native trimeric form for use in a vaccine.
  • If successful in clinical trials, Clover Biopharmaceuticals has the capacity to rapidly scale up the production of the vaccine using its in-house biomanufacturing capabilities.
  • Joshua Liang, Chief Strategy Officer of Clover Biopharmaceuticals and co-inventor of COVID-19 S-Trimer vaccine candidate said:
    At Clover Biopharmaceuticals, we are proud to receive CEPIs funding and support for Clover Australia, which are critical to enabling the ongoing development and acceleration of our COVID-19 S-Trimer vaccine program that utilizes our innovative Trimer-Tag platform technology.

Horizon Discovery CHOSOURCE™ platform supports development of immunotherapy for autoimmune diseases

Retrieved on: 
Wednesday, April 22, 2020
Biotechnology, Genetics, Health, Clinical trials, Articles, Life sciences, Biotechnology, Horizon Discovery, Industries, Biomanufacturing, Immunotherapy

Horizon Discovery Group plc (LSE: HZD) (Horizon, the Company or the Group), a global leader in the application of gene editing and gene modulation for cell line engineering, today announced that its cGMP-compliant CHOSOURCE platform has played a key role in generating a stable cell line for the development of an immunotherapy for autoimmune diseases.

Key Points: 
  • Horizon Discovery Group plc (LSE: HZD) (Horizon, the Company or the Group), a global leader in the application of gene editing and gene modulation for cell line engineering, today announced that its cGMP-compliant CHOSOURCE platform has played a key role in generating a stable cell line for the development of an immunotherapy for autoimmune diseases.
  • Its CHOSOURCE biomanufacturing platform helps companies to move from the DNA sequence of their potential biotherapeutic to clinical manufacturing as simply and rapidly as possible.
  • The combination of Horizons CHOSOURCE platform with Batavia Biosciencess STEP technology has enabled the rapid generation of a stable, highly-productive cell line that will help drive the clinical development of Immuteps promising immunotherapy.
  • Terry Pizzie, CEO, Horizon Discovery said: We are dedicated to ensuring availability of key technologies that can improve affordability of medicines worldwide.

RoosterBio Recognized by MTEC with a Multi-Institution Team "Prototype of the Year" Award to Accelerate Regenerative Medicine

Retrieved on: 
Wednesday, April 15, 2020
Articles, Life sciences, Branches of biology, Stem cells, Regenerative biomedicine, Emerging technologies, Biotechnology, Biomanufacturing, Regenerative medicine, Mesenchymal stem cell, Bone

MTEC's "Prototype of the Year" award spotlights breakthroughs developed by RoosterBio and its collaborators since MTEC's 2016 assigned contract of $7.8M to standardize large-scale manufacturing capabilities for clinical grade hMSCs.

Key Points: 
  • MTEC's "Prototype of the Year" award spotlights breakthroughs developed by RoosterBio and its collaborators since MTEC's 2016 assigned contract of $7.8M to standardize large-scale manufacturing capabilities for clinical grade hMSCs.
  • This team's success will facilitate broad adoption of cell manufacturing technology to empower product developers solving real world health challenges.
  • In response to the RFP titled "Biomanufacturing for Regenerative Medicine," the team executed on its project titled "Commercial Scale-Up of Bone Marrow-Derived Mesenchymal Stem Cells for Regenerative Medicine."
  • Since the MTEC contract ended in 2019, RoosterBio has been leveraging the work performed with bone marrow-derived hMSCs into other areas.

Visiongain Report Offers Transformative Insights on the $68.9bn Bioprocess Optimisation & Digital Biomanufacturing Market

Retrieved on: 
Thursday, April 9, 2020
Articles, Biotechnology, Life sciences, Natural sciences, Bioprocess engineering, Bioprocess, Biomanufacturing, Manufacturing

In this brand new 314-page report you will receive 206 charts all unavailable elsewhere.

Key Points: 
  • In this brand new 314-page report you will receive 206 charts all unavailable elsewhere.
  • The 314-page Visiongain report provides clear detailed insight into the Global Bioprocessing Optimisation and Digital Biomanufacturing market Discover the key drivers and challenges affecting the market.
  • By ordering and reading our brand-new report today you stay better informed and ready to act.
  • To request sample pages from this report please contact Sara Peerun at [email protected] or refer to our website: https://www.visiongain.com/report/global-bioprocess-optimisation-digital...
    Global Bioprocess Optimization and Digital Biomanufacturing submarket forecasts from 2019-2029 covering:
    Global Bioprocess and Digital Biomanufacturingregional and national market forecastsfrom 2019-2029 covering:
    Profiles of theleading Bioprocess and Biomanufacturing companies:

Visiongain Report Offers Transformative Insights on the $68.9bn Bioprocess Optimisation & Digital Biomanufacturing Market

Retrieved on: 
Thursday, April 9, 2020
Articles, Biotechnology, Life sciences, Natural sciences, Bioprocess engineering, Bioprocess, Biomanufacturing, Manufacturing

In this brand new 314-page report you will receive 206 charts all unavailable elsewhere.

Key Points: 
  • In this brand new 314-page report you will receive 206 charts all unavailable elsewhere.
  • The 314-page Visiongain report provides clear detailed insight into the Global Bioprocessing Optimisation and Digital Biomanufacturing market Discover the key drivers and challenges affecting the market.
  • By ordering and reading our brand-new report today you stay better informed and ready to act.
  • To request sample pages from this report please contact Sara Peerun at [email protected] or refer to our website: https://www.visiongain.com/report/global-bioprocess-optimisation-digital...
    Global Bioprocess Optimization and Digital Biomanufacturing submarket forecasts from 2019-2029 covering:
    Global Bioprocess and Digital Biomanufacturingregional and national market forecastsfrom 2019-2029 covering:
    Profiles of theleading Bioprocess and Biomanufacturing companies:

SCIEX and Intabio Collaborate to Accelerate Biopharma Drug Development

Retrieved on: 
Wednesday, April 8, 2020
Medical devices, General Health, Automotive, Hospitals, Science, Genetics, Clinical trials, FDA, Entertainment, Biotechnology, Other Manufacturing, Health, Other Science, Research, Manufacturing, Environment, Pharmaceutical, Articles, Natural sciences, Life sciences, Biopharmaceuticals, Capillary electrophoresis, Chromatography, Electrophoresis, Forensics, Polymerase chain reaction, Biomanufacturing, SCIEX, Intabio

This collaboration is geared to accelerate and transform biotherapeutic development and biomanufacturing.

Key Points: 
  • This collaboration is geared to accelerate and transform biotherapeutic development and biomanufacturing.
  • By coupling iCIEF separations directly to leading high resolution MS systems, the Blaze system eliminates a serious laboratory bottleneck for drug developers, said Lena Wu, Ph.D., Intabio CEO and co-founder.
  • Blaze integration with SCIEX flagship MS platforms will enable biopharma to accelerate critical decisions and ultimately reduce development timelines.
  • This work demonstrates our continued commitment to collaborate with key innovators to develop practical solutions for our biopharmaceutical customers, said Mani Krishnan, Vice President of Global Biopharma and Capillary Electrophoresis at SCIEX.

Next-Generation Biomanufacturing Market Landscape 2019-2029 - Market Leaders are Collaborating with Technology-Based Startups to Gain Their Expertise in Technology

Retrieved on: 
Friday, March 27, 2020
Articles, Life sciences, Economy, Biopharmaceuticals, Biomanufacturing, Biotechnology, Food industry, Pharmaceutical industry, Startup company

The Global Next-Generation Biomanufacturing Market Report projects the market to grow at a significant CAGR of 10% during the forecast period, 2019-2029.

Key Points: 
  • The Global Next-Generation Biomanufacturing Market Report projects the market to grow at a significant CAGR of 10% during the forecast period, 2019-2029.
  • Most of the market leaders are collaborating with technology-based startups to gain their expertise in technology.
  • Most of the market leaders are collaborating with technology-based startups to gain their expertise in technology.
  • This market intelligence report provides a multidimensional view of the global next-generation biomanufacturing market in terms of market size and growth potential.

Global Next-Generation Biomanufacturing Markets, 2019-2029: Focus on Workflow, Product Type, Medical Applications, End-users, and Competitive Landscape - ResearchAndMarkets.com

Retrieved on: 
Thursday, March 26, 2020
Health, Biotechnology, Articles, Life sciences, Biopharmaceuticals, Biotechnology, Biomanufacturing, Food industry, Pharmaceutical industry, Compound annual growth rate

The "Global Next-Generation Biomanufacturing Market: Focus on Workflow, Product Type, Medical Applications, End Users, 5 Regional Data, 19 Countries' Data, and Competitive Landscape - Analysis and Forecast, 2019-2029" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Next-Generation Biomanufacturing Market: Focus on Workflow, Product Type, Medical Applications, End Users, 5 Regional Data, 19 Countries' Data, and Competitive Landscape - Analysis and Forecast, 2019-2029" report has been added to ResearchAndMarkets.com's offering.
  • The Global Next-Generation Biomanufacturing Market Report projects the market to grow at a significant CAGR of 10% during the forecast period, 2019-2029.
  • Monoclonal antibody product segment with relatively high market approval rates is dominating the next-generation biomanufacturing market, by the medical application.
  • In terms of end-users, commercial-stage end-user dominated the global next-generation biomanufacturing market and was valued at $11.39 billion in 2018.

Aldevron Names Vijay Surapaneni as Vice President Biomanufacturing Operations

Retrieved on: 
Thursday, March 12, 2020
Infectious diseases, FDA, Genetics, Clinical trials, Cardiology, Stem cells, Biotechnology, Pharmaceutical, Health, Oncology, Articles, Life sciences, Industries, Biopharmaceuticals, Biomanufacturing, Food industry, Pharmaceutical industry, Biotechnology, Manufacturing

Aldevron, a global leader in the custom development and manufacture of plasmid DNA, proteins, mRNA and antibodies for the biotech industry, has hired Vijay Surapaneni as its Vice President of Biomanufacturing Operations.

Key Points: 
  • Aldevron, a global leader in the custom development and manufacture of plasmid DNA, proteins, mRNA and antibodies for the biotech industry, has hired Vijay Surapaneni as its Vice President of Biomanufacturing Operations.
  • View the full release here: https://www.businesswire.com/news/home/20200312005120/en/
    Aldevron Names Vijay Surapaneni as Vice President Biomanufacturing Operations (Photo: Business Wire).
  • Surapaneni brings over 30 years of global leadership experience in pharmaceutical and device technology, operations, and engineering.
  • I am excited about the opportunity to join Aldevron and drive the execution of the growth strategies and talent development, commented Surapaneni.